Type 2 Diabetes | China In-Depth | China | 2024
Type 2 diabetes (T2D) remains one of the biggest public health concerns in China, where the disease’s prevalence is globally the highest. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and GLP-1 and GIP / GLP-1 receptor agonists in earlier lines of therapy is increasing. The GLP-1 and GIP / GLP-1 receptor agonists combine superior glucose-lowering and weight-loss capabilities in once-weekly and oral formulations, making them very appealing to both patients and physicians. The T2D pipeline mainly comprises drugs from established drug classes, and we anticipate that the launch of late-phase therapies with more-convenient dosing options will further drive market growth over the 2023-2033 forecast period. In this report, we explore how unmet needs, pricing, coverage, and regulatory reforms in China will impact the success of current and future players in this highly lucrative market.
QUESTIONS ANSWERED
- How large is China’s drug-treatable T2D population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s T2D market, and why?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of T2D in China?
- What are the key market access considerations, and how will they affect the uptake of emerging therapies for T2D in China?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Release Date
April 2024
Geographies
China
Primary Research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 endocrinologists
Epidemiology
Diagnosed prevalence of type 2 diabetes in China, with urban and rural breakup. Clinically and market-relevant drug-treatable populations
Forecast
10-year, annualized, drug-level sales and patient share of key type 2 diabetes therapies through 2033, based on primary and secondary market research to formulate bottom-up assumptions
Emerging Therapies
Phase 3/PR: 10+ drugs; Phase 2: 10+ drugs.
NEW: China In-Depth reports include a custom drug modeler. This tool enables clients to input their own assumptions for a drug and forecast three scenarios that can be directly compared with Clarivate’s projections for drugs included in the patient-based market forecast. To access the tool, download the Market Forecast Dashboard file on the Insights Platform.
